Characterization of CPDM's Patient Derived Models

In this section

CPDM supports the characterization of patient derived models using various genomic and molecular approaches. Our standard approaches include:

Targeted Cancer Panel (ModelSeq)
Lineage Marker Expression NanoString panel (ModelExpress)
Low Pass WGS (ModelLP)
WES, WGS, RNASeq
STR Fingerprinting
Histopathology
In vitro Cell Viability Assay with PDX/PDCL in our semi-automated IncuCyte S3 live cell imaging platform and Tecan D300e drug dispensing platform
In vivo Studies with PDX/PDCL

Once characterization data is acquired, data will be uploaded to a private instance of cBioPortal for analysis and visualization.

Please email models@dfci.harvard.edu to learn more about our model characterization services.